Search
Aclaris Therapeutics Inc
ACRSAdd to Watchlist
5.250USD
+0.050+0.96%
Close 07-31 16:00（ET）Quotes delayed by 15 min
733.18MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Aclaris Therapeutics Inc is 8.91, ranking 36 out of 385 in the Biotechnology & Medical Research industry. The average price target is 7.00, with a high of 16.00 and a low of 2.00.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
9.773
Target Price
+87.94%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Aclaris Therapeutics Inc
ACRS
12
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Aclaris Therapeutics Inc's expected revenue for the next quarter?
Aclaris Therapeutics Inc's expected revenue is 1.38M.
What is Aclaris Therapeutics Inc's price target?
Analysts forecast that Aclaris Therapeutics Inc's price target is USD 7.00, with the highest forecast at USD 16.00 and the lowest forecast at USD 2.00.
How have Aclaris Therapeutics IncACRS's recent earnings per share performed?
The market expectation was USD -0.15, while Aclaris Therapeutics IncACRS's earnings per share (EPS) for the previous quarter was USD -0.16. EPS for the next quarter is expected at USD -0.16.
What is the analyst rating for Aclaris Therapeutics Inc?
Based on the ratings of Aclaris Therapeutics Inc's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.